Early Changes of the Standardized Uptake Values (SUVmax) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer
Marianna Sirico(Istituti Ospitalieri di Cremona), Daniele Generali(University of Trieste), Claudio Vernieri(Fondazione IRCCS Istituto Nazionale dei Tumori), Ottavia Bernocchi(University of Trieste), Fabiola Giudici(University of Padua), Giuseppina Barbieri(Istituti Ospitalieri di Cremona), Giulia Bianchi, Maria Rosa Cappelletti(University of Trieste), Valeria Cervoni(University of Trieste), Nicoletta Ziglioli(Istituti Ospitalieri di Cremona), Federico Nichetti(Fondazione IRCCS Istituto Nazionale dei Tumori), Carla Strina(Istituti Ospitalieri di Cremona), Silvia Paola Corona(Hôpital Cardiologique du Haut-Lévêque), Martina Dester(Istituti Ospitalieri di Cremona), Filippo de Braud(University of Milan), Manuela Milani(Humanitas University), Navid Sobhani(University of Trieste)
Cited by 9
Related Papers
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas
|Nature Genetics|2013|709
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials
|The Lancet Oncology|2019|537